Respiratory drug group () took a step forward in developing a treatment for a fatal lung disease this month when it announced positive results from its on-going collaboration with .
Chief executive Richard Marsden tells Proactive “fibrosis is a really hot area and lots of the big pharma companies want drugs which are anti-fibrotic”.
He adds that the next thing for the company is to start clinical trials in 2017, but also notes that Synairgen will work on additional partnership deals.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
